SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
SGNT was delisted on the 29th of August, 2016.
136 hedge funds and large institutions have $604M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 62 increasing their positions, 35 reducing their positions, and 18 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 35
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
7% more funds holding
Funds holding: 127 → 136 (+9)
5% more capital invested
Capital invested by funds: $576M → $604M (+$27.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$21.9M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$9.28M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.87M |
| 4 |
SFM
Soros Fund Management
New York
|
+$5.55M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$41.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$16.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$15.3M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.34M |
| 5 |
BAMS
Bellevue Asset Management (Switzerland)
Kuesnacht,
Switzerland
|
-$2.33M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
151
Quantbot Technologies
New York
| – | -$42K | -1,849 | Closed |
|
|
AP
152
Advisors Preferred
Rockville,
Maryland
| – | -$31.8K | -1,367 | Closed |
|
153
SEI Investments
Oaks,
Pennsylvania
| – | -$7K | -305 | Closed |
|
SGNT Hedge Fund Activity: Q2 2015 in Review
136 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q2 2015, worth a combined $604M — up 4.7% from $576M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SGNT positions and 18 closed out — a net gain of 9 holders — while 62 added to existing stakes and 35 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $21.9M. The largest seller was Morgan Stanley, cutting an estimated $41.4M.
- 136 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q2 2015, up from 127 in Q1 2015.
- Funds reported $604M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q2 2015, up 4.7% quarter-over-quarter.
- 27 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q2 2015 and 18 closed out, a net change of +9 holders.
- The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q2 2015 was HealthCor Management, an estimated $21.9M added.
- The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q2 2015 was Morgan Stanley, an estimated $41.4M sold.
Based on aggregated 13F filings for Q2 2015.